Articles related to ALZHEIMER'S/DEMENTIA

In the confirmatory trial, Clarity AD, of 1,795 patients with early AD, findings showed a reduction of dementia scoring of 27% vs. placebo. These findings were seen as early as 6 months.

Palliative care (PC) can help reduce emergency department use, hospitalizations, and symptom burden across a spectrum of diseases. To assist clinicians in keeping their expertise current, the authors reviewed and summarized the top PC articles of 2020. The analysis included 28 PC intervention trials for heart failure, chronic obstructive pulmonary disease, and dementia.

On September 20, 2022, Alzheon Inc. announced promising results from its phase 2 trial of oral ALZ-801 (valiltramiprosate) in patients with early AD. The drug decreased p-tau181 levels, reduced brain atrophy, and improved cognitive skills in the trial.

The TRAILBLAZER-ALZ Randomized Clinical Trial According to the findings of post-hoc analysis for patients who received donanemab treatment, baseline amyloid levels were directly related to the extent of amyloid reduction and inversely related to the likelihood of obtaining total amyloid clearance. In patients with complete amyloid clearance and in brain areas discovered later in the pathologic sequence, the donanemab-induced slowing of tau was more severe. To support the aforementioned findings, data from additional trials would be crucial, particularly information on treatment response according to APOE ε4 status.

The optimal dose of daily steps—the amount with the greatest dementia risk reduction—was 9,826 steps, with the minimum step dose, or the amount at which dementia risk was half of the maximal reduction, was 3,826 steps per day. See the original article on JAMA Neurology.

Among 150 people ages 65 to 88, investigational transcranial alternating current stimulation for 20 minutes over 4 consecutive days produced selective improvements in working and long-term memory in older adults that lasted for at least a month The rate of memory improvement over 4 days predicted the size of memory benefits 1 month later, the researchers found. Moreover, people with lower baseline cognitive function experienced larger and longer lasting memory improvements. “We found that by applying extremely weak electrical current safely and noninvasively to the prefrontal cortex at a high frequency, we could selectively improve long-term memory in older people aged 65 to 88 years old without changing short-term memory.” Robert Reinhart, PhD, Boston University in Nature Neuroscience